HK1061652A1 - Solid pharmaceutical formulations comprising modafinil - Google Patents
Solid pharmaceutical formulations comprising modafinilInfo
- Publication number
- HK1061652A1 HK1061652A1 HK04104701A HK04104701A HK1061652A1 HK 1061652 A1 HK1061652 A1 HK 1061652A1 HK 04104701 A HK04104701 A HK 04104701A HK 04104701 A HK04104701 A HK 04104701A HK 1061652 A1 HK1061652 A1 HK 1061652A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- modafinil
- pharmaceutical formulations
- solid pharmaceutical
- compositions
- disintegrants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29369501P | 2001-05-25 | 2001-05-25 | |
US10/155,913 US7297346B2 (en) | 2001-05-25 | 2002-05-23 | Pharmaceutical formulations of modafinil |
PCT/US2002/016369 WO2002096401A1 (en) | 2001-05-25 | 2002-05-24 | Solid pharmaceutical formulations comprising modafinil |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1061652A1 true HK1061652A1 (en) | 2004-09-30 |
Family
ID=26852708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04104701A HK1061652A1 (en) | 2001-05-25 | 2004-06-30 | Solid pharmaceutical formulations comprising modafinil |
Country Status (20)
Country | Link |
---|---|
US (1) | US7297346B2 (pt) |
EP (1) | EP1397127B8 (pt) |
JP (1) | JP4443119B2 (pt) |
KR (1) | KR100911779B1 (pt) |
CN (1) | CN1318026C (pt) |
AT (1) | ATE357228T1 (pt) |
AU (1) | AU2002318155B8 (pt) |
BR (1) | BRPI0210085B8 (pt) |
CA (1) | CA2448456C (pt) |
DE (1) | DE60219005T2 (pt) |
ES (1) | ES2281527T3 (pt) |
HK (1) | HK1061652A1 (pt) |
IL (1) | IL158959A (pt) |
MX (1) | MXPA03010705A (pt) |
MY (1) | MY129376A (pt) |
NO (1) | NO328805B1 (pt) |
NZ (1) | NZ530040A (pt) |
TW (1) | TWI321475B (pt) |
WO (1) | WO2002096401A1 (pt) |
ZA (1) | ZA200309978B (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1309547E (pt) | 2000-07-27 | 2007-03-30 | Teva Pharma | Modafinil cristalino e puro, e processo para a sua preparação |
US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
US20040048931A1 (en) | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
WO2004010979A1 (en) * | 2002-07-25 | 2004-02-05 | Ranbaxy Laboratories Limited | Processes for the preparation of oral dosage formulations of modafinil |
US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
CA2420180A1 (en) * | 2003-02-28 | 2004-08-28 | Bernard Charles Sherman | Tablets comprising modafinil |
CA2519117C (en) * | 2003-03-17 | 2010-03-02 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
AR046410A1 (es) * | 2003-09-18 | 2005-12-07 | Cephalon Inc | Composiciones farmaceuticas para la liberacion modificada de modafinilo |
UA94380C2 (ru) * | 2003-09-18 | 2011-05-10 | Сефалон, Інк. | Фармацевтические композиции модафинила с модифицированным высвобождением |
US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
US20050137264A1 (en) * | 2003-12-22 | 2005-06-23 | Patel Ashish A. | Modafinil compositions |
EP1865980A4 (en) * | 2005-04-08 | 2009-11-11 | Shire Llc | ABUSEFUL AMPHETAMINE PRODRUGS |
US20070048373A1 (en) * | 2005-08-30 | 2007-03-01 | Cima Labs Inc. | Dried milled granulate and methods |
US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
KR101431711B1 (ko) * | 2008-05-07 | 2014-08-21 | 삼성전자 주식회사 | 발광 장치 및 발광 시스템의 제조 방법, 상기 방법을이용하여 제조한 발광 장치 및 발광 시스템 |
US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
DK2649187T3 (da) | 2010-12-08 | 2018-01-29 | Codexis Inc | Biokatalysatorer og fremgangsmåder til syntesen af armodafinil |
US20130267612A1 (en) * | 2010-12-21 | 2013-10-10 | Akzo Nobel Chemicals International B.V. | Instant powders for aqueous cosmetic applications |
FR2987266B1 (fr) | 2012-02-28 | 2014-12-19 | Debregeas Et Associes Pharma | Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application |
US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1570994A (en) * | 1923-11-20 | 1926-01-26 | William A Cook | Spring-forming die |
GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
GB9225492D0 (en) * | 1992-12-05 | 1993-01-27 | Glaxo Group Ltd | Amine derivatives |
US5843347A (en) * | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
FR2702968B1 (fr) * | 1993-03-23 | 1995-06-23 | Lafon Labor | Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation . |
FR2706767B1 (pt) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
US5618845A (en) * | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
CN1277550A (zh) * | 1997-09-11 | 2000-12-20 | 尼科梅德丹麦有限公司 | 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物 |
CN1335769A (zh) * | 1998-12-18 | 2002-02-13 | 艾博特公司 | 双丙戊酸钠的控释制剂 |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
US6204245B1 (en) * | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
US20010034373A1 (en) * | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
US6492396B2 (en) * | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
US6670358B2 (en) * | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
-
2002
- 2002-05-23 DE DE60219005T patent/DE60219005T2/de not_active Expired - Lifetime
- 2002-05-23 AT AT02747859T patent/ATE357228T1/de not_active IP Right Cessation
- 2002-05-23 US US10/155,913 patent/US7297346B2/en not_active Expired - Fee Related
- 2002-05-23 IL IL158959A patent/IL158959A/en active IP Right Grant
- 2002-05-23 KR KR1020037015397A patent/KR100911779B1/ko not_active IP Right Cessation
- 2002-05-23 MX MXPA03010705A patent/MXPA03010705A/es active IP Right Grant
- 2002-05-23 ES ES02747859T patent/ES2281527T3/es not_active Expired - Lifetime
- 2002-05-24 AU AU2002318155A patent/AU2002318155B8/en not_active Expired
- 2002-05-24 NZ NZ530040A patent/NZ530040A/en not_active IP Right Cessation
- 2002-05-24 BR BRPI0210085A patent/BRPI0210085B8/pt not_active IP Right Cessation
- 2002-05-24 JP JP2002592912A patent/JP4443119B2/ja not_active Expired - Lifetime
- 2002-05-24 CA CA2448456A patent/CA2448456C/en not_active Expired - Fee Related
- 2002-05-24 MY MYPI20021932A patent/MY129376A/en unknown
- 2002-05-24 WO PCT/US2002/016369 patent/WO2002096401A1/en active Application Filing
- 2002-05-24 CN CNB028104919A patent/CN1318026C/zh not_active Expired - Lifetime
- 2002-05-24 EP EP02747859A patent/EP1397127B8/en not_active Expired - Lifetime
- 2002-05-27 TW TW091111169A patent/TWI321475B/zh not_active IP Right Cessation
-
2003
- 2003-11-24 NO NO20035211A patent/NO328805B1/no not_active IP Right Cessation
- 2003-12-23 ZA ZA2003/09978A patent/ZA200309978B/en unknown
-
2004
- 2004-06-30 HK HK04104701A patent/HK1061652A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BRPI0210085B1 (pt) | 2020-11-10 |
KR100911779B1 (ko) | 2009-08-12 |
DE60219005D1 (de) | 2007-05-03 |
BRPI0210085A (pt) | 2004-06-29 |
EP1397127B8 (en) | 2008-02-20 |
KR20040005986A (ko) | 2004-01-16 |
ZA200309978B (en) | 2005-05-25 |
MXPA03010705A (es) | 2004-05-27 |
WO2002096401A1 (en) | 2002-12-05 |
EP1397127A1 (en) | 2004-03-17 |
US7297346B2 (en) | 2007-11-20 |
NO328805B1 (no) | 2010-05-18 |
NO20035211D0 (no) | 2003-11-24 |
DE60219005T2 (de) | 2007-12-13 |
NZ530040A (en) | 2005-11-25 |
JP2004532863A (ja) | 2004-10-28 |
EP1397127B1 (en) | 2007-03-21 |
JP4443119B2 (ja) | 2010-03-31 |
IL158959A0 (en) | 2004-05-12 |
BRPI0210085B8 (pt) | 2021-07-20 |
CN1511031A (zh) | 2004-07-07 |
MY129376A (en) | 2007-03-30 |
AU2002318155B2 (en) | 2007-03-01 |
CN1318026C (zh) | 2007-05-30 |
ATE357228T1 (de) | 2007-04-15 |
IL158959A (en) | 2010-06-30 |
CA2448456A1 (en) | 2002-12-05 |
ES2281527T3 (es) | 2007-10-01 |
TWI321475B (en) | 2010-03-11 |
CA2448456C (en) | 2010-07-27 |
AU2002318155B8 (en) | 2008-05-15 |
US20030022940A1 (en) | 2003-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1061652A1 (en) | Solid pharmaceutical formulations comprising modafinil | |
GB0004128D0 (en) | Novel compounds | |
MY134136A (en) | Novel compounds comprising jak3 kinase inhibitors | |
WO2002100845A8 (en) | Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | |
MXPA04004498A (es) | Derivados de n-adamantilmetil e intermediarios como composiciones farmaceuticas y procesos para su preparacion. | |
WO2003000200A3 (en) | β-2'-OR 3'-HALONUCLEOSIDES | |
YU63703A (sh) | 6-supstituisani pirido-pirimidini | |
BR0314514A (pt) | Formulações farmacêuticas de modafinil | |
PL367682A1 (en) | Dolastatin 10 derivatives | |
MY128924A (en) | Novel compounds | |
MY140081A (en) | Pharmaceutical formulations of modafinil | |
MXPA03010158A (es) | Sulfonamidas. | |
IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
NO20043016L (no) | 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav | |
SE0102716D0 (sv) | Novel compounds | |
MXPA03008801A (es) | Aril oxima-piperazinas utiles como antagonistas de ccr5. | |
DE60201074D1 (en) | Pyrazolopyridinderivate | |
AU2002357740A1 (en) | Pyrazolo-pyridine derivatives as antiherpes agents | |
MXPA04005151A (es) | Compuestos terapeuticos. | |
SI1651596T1 (sl) | Novi derivati ditiobis aminobutan sulfonatov in sestavki ki jih vsebujejo | |
DE60212130D1 (en) | Carvedilolpolymorph | |
DE60214004D1 (en) | Tricyclische epoxide | |
EP1444247A4 (en) | NEW TIBOLON FORMULATIONS | |
DE60208541D1 (de) | Antibakterielle mittel | |
MXPA04006120A (es) | Piperidin-2,6-dionas sustitudas heterociclicamente en posicion 3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: CORRECTION OF THE EP APPLICATION FILING DATE AND THE INTERNATIONAL APPLICATION FILING DATE FROM 23.05.2002 TO 24.05.2002. |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160524 |